



Company Overview

Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all which could help to increase treatment compliance and improve patient outcomes.

The Company's three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents. The lead assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability, for which no treatment currently exists; and (iii) GTX-101, a topical spray, targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 12 2024, 12:00 AM EST

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Feb 1 2024, 12:00 AM EST

Stock Overview

Symbol	ACST	LifeSci Advisors
Exchange	Nasdaq	Mike Moyer
Market Cap	28.86m	Managing Director
Last Price	\$3.07	T: 617-308-4306
52-Week Range	\$1.72 - \$3.84	mmoyer@lifesciadvisors.com

04/18/2024 03:50 PM EDT

Investor Relations

Management Team

Prashant Kohli

Chief Executive Officer and Director

Robert J. DeAversano

Principal Financial Officer and Principal Accounting Officer

Dr. R. Loch Macdonald, MD, PhD

Chief Medical Officer

Carrie D'Andrea

Vice President Clinical Operations

Amresh Kumar, PhD

Vice President Program Management

Acasti Pharma Inc.

103 Carnegie Center
Suite 300
Princeton, NJ 08540

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.